• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Preclinical

Diacylglycerol kinase α is a potential target for X-linked lymphoproliferative disease treatment [PreClinical]

byChristine YoonandJessica Lau
January 22, 2016
in Preclinical
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Diacylglyerol kinase α (DGKα) inhibitors R59949 and R59022 partially restored restimulation-induced cell death (RICD) in activated T cells from patients with X-linked lymphoproliferative disease (XLP-1).

2. In a mouse model of XLP-1, treatment with R59022 led to improved RICD as measured by fewer inflammatory lesions in the liver and overall decreased activation of the immune system relative to control treatment.

Evidence Rating Level: 2 (Good)           

Study Rundown: XLP-1 is a congenital immune disorder that causes the accumulation of activated T cells in response Epstein-Barr virus (EBV) infections. Due in part to the ineffective clearance of T cells through the RICD process, this disease leads to tissue damage caused by the excessive infiltration of immune cells into organs such as the liver and bone marrow. Because the protein that regulates DGKα levels is defective in XLP-1 patients, the authors of this study investigated DGKα inhibitors as potential therapeutics to improve RICD in XLP-1 T cells.

Initial studies in vitro demonstrated that when XLP-1 patient-derived T cells were modified to no longer express DGKα or were treated with R59949 or R59022 to pharmacologically inhibit DGKα, cell death increased upon restimulation. To model EBV infection in XLP-1 patients, the authors utilized a genetic murine model of XLP-1 in which mice were infected with lymphocytic choriomeningitis virus (LCMV). XLP-1 mice treated with R59022 showed a decrease in LCMV-specific active T cells, hepatic inflammatory lesions, and serum levels of the proinflammatory protein interferon gamma (IFNγ). Notably, treatment did not affect the ability of mice to resolve the viral infection over an eight-day period.

While the authors did not report on the effects of DGKα inhibition in other immune cell types relevant in XLP-1, this work demonstrates the possible therapeutic benefit of using DGKα inhibitors to restore the RICD regulatory mechanism in the T cells of XLP-1 patients. Further studies will need to address the ability of DGKα inhibitors to improve overall survival, as overexpansion of T cells is often fatal in XLP-1 patients with EBV infection.

RELATED REPORTS

Long-term Outcomes of Patients with Crohn’s Disease Treated with Risankizumab

2 Minute Medicine: Pharma Roundup- Obesity RNA deal, at-home Alzheimer’s dosing, oncology royalty financing, and first Bruton’s Tyrosine Kinase Inhibitor for Immune Thrombocytopenia [September 3, 2025]

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Click to read the study in Science Translational Medicine

Relevant Reading: SAP gene transfer restores cellular and humoral immune function in a murine model of X-linked lymphoproliferative disease

In-Depth [animal study]: The authors first established the potential to improve RICD by targeting DGKα in T cells using in vitro studies. Small-interfering RNA was utilized to decrease the expression of DGKα in patient-derived T cells. The DGKα loss significantly increased the rate of T cell death upon stimulation with 50-100 ng/mL of the anti-CD3 antibody OKT3 (p<0.016). Pharmacological inhibition of DGKα activity by R59949 or R59022 demonstrated a similar trend of enhanced cell death.

To test the effect of DGKα inhibition on immune cell function in vivo, Sh2d1a−⁄− mice were used as a model of XLP-1. Four days after infection with 2 × 105 plaque-forming units of LCMV, mice (n=6 to 10 in each cohort) were treated twice a day with 2 mg/kg body weight of R59022 via intraperitoneal injection. Eight days after infection, spleens and livers were collected from wild-type and XLP-1 mice, treated and untreated, for analysis.

Treated XLP-1 mice showed a significant decrease in the absolute number of splenic and hepatic CD8+ T cells specific to LCMV virus (p=0.0006 and 0.0009, respectively), whereas wild-type mice were unaffected by treatment. Histology samples of liver tissue from XLP-1 mice were analyzed, and compared to the untreated group, treatment with inhibitor led to a significant decrease in the number and size of infiltration lesions containing greater than 8 lymphocytes (p<0.0001). Enzyme linked immunosorbent assays showed a significant decrease in serum levels of IFNγ in treated XLP-1 mice compared to untreated mice (p=0.0013). Nonetheless, R59022-treated mice showed undetectable viral loads in the spleen and liver at the end of the 8-day experimental period.

Image: CC/Lisa Gross

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

The MADIT-CRT trial: Cardiac resynchronization therapy in heart failure [Classics Series]

Next Post

Women with pregnancy-associated melanoma at greater risk of metastasis, recurrence

RelatedReports

Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Chronic Disease

Long-term Outcomes of Patients with Crohn’s Disease Treated with Risankizumab

September 3, 2025
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Cardiology

2 Minute Medicine: Pharma Roundup- Obesity RNA deal, at-home Alzheimer’s dosing, oncology royalty financing, and first Bruton’s Tyrosine Kinase Inhibitor for Immune Thrombocytopenia [September 3, 2025]

September 3, 2025
Imatinib safe and effective as long-term treatment for chronic myeloid leukemia: The IRIS trial
Hematology

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

September 2, 2025
Cardiology

An absence of cardiovascular risk factors is linked to over ten additional healthy years

September 2, 2025
Next Post
Women with pregnancy-associated melanoma at greater risk of metastasis, recurrence

Women with pregnancy-associated melanoma at greater risk of metastasis, recurrence

Labor and delivery patient safety bundle associated with improved outcomes

Labor and delivery patient safety bundle associated with improved outcomes

AAP addresses neonatal pain prevention

AAP addresses neonatal pain prevention

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Long-term Outcomes of Patients with Crohn’s Disease Treated with Risankizumab
  • 2 Minute Medicine: Pharma Roundup- Obesity RNA deal, at-home Alzheimer’s dosing, oncology royalty financing, and first Bruton’s Tyrosine Kinase Inhibitor for Immune Thrombocytopenia [September 3, 2025]
  • Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.